The discovery of JAK2V617F has rejuvenated interest in Janus kinase (JAK)-signal transducer and activator of transcription (STAT), both as an oncogenic pathway and a drug target in BCR-ABL1-negative myeloproliferative neoplasms (MPN). However, the complexity of these diseases in terms of both clonal structure and mutation repertoire makes it unlikely that JAK inhibitor therapy will replicate what has been achieved with imatinib in chronic myeloid leukemia. Consistent with this view, JAK inhibitor therapy in myelofibrosis has not yet produced complete or partial remissions. However, most patients treated with a JAK2 (TG101348) or JAK1/2 (INCB018424) inhibitor experienced substantial improvement in constitutional symptoms and reduction in spleen size; the mechanism of action for INCB018424 includes anti-JAK1-mediated downregulation of proinflammatory cytokines. These observations complicate the choice of primary end points in clinical trials that would be robust enough to support regulatory approval. TG101348 and INCB018424 are the vanguard of JAK inhibitor therapy in myelofibrosis, but newer JAK inhibitors might have a broader spectrum of activity; preliminary results with CYT387 suggest responses in both anemia and splenomegaly. Outstanding issues regarding these drugs include identification of the optimal dosing strategy, their role (if any) in the treatment of polycythemia vera or essential thrombocythemia, and the potential for combining them with other therapeutic agents.
Introduction BCR-ABL1 is the disease-causing mutation in chronic myelogenous leukemia and kinase inhibitors (for example, imatinib, nilotinib and dasatinib) that target the mutant oncoprotein have been shown to be therapeutically effective. 1 In contrast, the genetic underpinnings of BCR-ABL1-negative myeloproliferative neoplasms (MPN), which include, polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF), remain poorly understood and their treatment suboptimal. Historically, several avenues of investigation had suggested a key role for constitutively active JAK-STAT in the pathogenesis of these diseases. 2 The discovery of JAK2V617F in 2004 (first reported in 2005) and its occurrence in the majority of patients with PV, ET or PMF, validated this assumption and encouraged the development of JAK-STAT targeted therapy in MPN. [3] [4] [5] [6] However, current evidence suggests that JAK2V617F (or other JAK-STAT activating mutations in MPN) does not represent the disease-initiating event, but rather defines a MPN subclone that collaborates with other mutations to influence disease phenotype. 7 Furthermore, JAK2V617F presence or increased allele burden does not appear to affect thrombosis risk, survival or leukemic transformation, whereas low allele burden has been associated with both inferior survival and a higher risk of developing acute leukemia. [8] [9] [10] JAK2V617F results from a somatic G to T mutation involving JAK2 exon 14, which leads to nucleotide change at position 1849 and the substitution of valine to phenylalanine at codon 617. 3 The mutation affects the non-catalytic (pseudo-kinase) domain and disrupts its kinase-regulatory activity. Other JAK-STAT-relevant mutations in MPN involve JAK2 exon 12, MPL exon 10 and LNK. JAK2 exon 12 mutations are relatively specific to JAK2V617F-negative PV, accounting for approximately 3% of all PV cases. 11, 12 JAK2 exon 12 mutations target a 'hot spot'-spanning amino acid residues 536-547 and include point mutations, deletions and insertions. MPLW515L, MPLW515K and other exon 10 MPL mutations occur in approximately 3% of patients with ET and 10% of those with PMF. [13] [14] [15] [16] [17] As is the case with JAK2V617F, the presence of either JAK2 exon 12 or MPL mutation has not been shown to affect survival or fibrotic or leukemic transformation.
Loss of negative feedback regulation is another mechanism for JAK-STAT activation. LNK (SH2B3) is an adaptor protein that negatively regulates thrombopoietin-MPL-mediated JAK2 activation; it has been shown to downregulate signaling downstream of MPLW515L and JAK2V617F in vitro.
18,19
LNK exon 2 mutations are infrequently encountered in chronic phase MPN and JAK2V617F-negative erythrocytosis 20 but a higher (13%) incidence has been demonstrated in blast-phase MPN. 21 Most LNK mutations target an exon 2 'hot spot' in the pleckstrin homology domain spanning residues E208-D234. 
IKZF1
27 and EZH2 28 have also been described in some MPN patients, however, these are not directly implicated in activating JAK-STAT.
Myelofibrosis (MF) is a BCR-ABL1-negative MPN that presents either de novo (PMF) or post PV or ET. Clinical features include progressive anemia, marked hepatosplenomegaly, constitutional symptoms (for example, fatigue, night sweats, fever, cachexia and weight loss), bone pain, cough, splenic infarcts, pruritus, thrombosis and bleeding. 29 Ineffective erythropoiesis and extramedullary hematopoiesis are the main causes of anemia and organomegaly, respectively. Median survival ranges from o2 years to over 15 years on the basis of the presence or absence of well-defined clinical adverse features: advanced age, constitutional symptoms, anemia, transfusion need, thrombocytopenia, leukocytosis, circulating blasts and unfavorable karyotype. 30 Causes of death include leukemic transformation that occurs in approximately 20% of patients. 31 Given the current lack of disease-modifying drug therapy and significant symptom burden in MF, 32, 33 it is important to pursue palliative therapies, particularly those that alleviate anemia, hepatosplenomegaly or constitutional symptoms. We discuss below the prevalence, current treatment and therapeutic value of JAK inhibitors, in the context of MF-associated organomegaly, anemia and constitutional symptoms. We will then address the appropriateness of using treatment efficacy in any one of these parameters as a primary end point in clinical trials, with the goal of supporting a new drug application for labeling claims in MF. For the purposes of the current perspective, we focus on three JAK inhibitors with the most promising therapeutic activity, so far, in MF: INCB018424, TG101348 and CYT387.
Splenomegaly in MF

Prevalence and clinical aspects
Marked organomegaly, resulting primarily from extramedullary hematopoiesis, is a characteristic feature of MF; the prevalence of palpable splenomegaly and hepatomegaly in PMF is approximately 90 and 50%, respectively. 30, 34 Associated symptoms include abdominal pain/discomfort, early satiety, disturbed bowel movement, urinary frequency and peripheral edema. More dire complications include splenic infarction and symptomatic portal hypertension (ascites and variceal bleeding). Marked splenomegaly can also exacerbate anemia and thrombocytopenia due to hypersplenism.
Current treatment approaches
The first-line treatment for symptomatic splenomegaly in MF is hydroxyurea. In patients with marked splenomegaly, however, the benefit from hydroxyurea therapy is modest; in one study, for example, only 17% experienced a X50% reduction in palpable spleen size, with a significantly higher response rate in JAK2V617F-positive cases. 35 A 40% hydroxyurea-induced response rate in splenomegaly was reported in another recent study of patients with MF. 36 Hydroxyurea-refractory splenomegaly is often managed by splenectomy, which also improves anemia and thrombocytopenia in some patients. However, the overall benefit of splenectomy is undermined by notable peri-operative mortality (B9%) and morbidity (B28%) and post-splenectomy complications include infections, thrombohemorrhagic events, extreme thrombocytosis or leukocytosis and accelerated hepatomegaly. 37 Splenic or hepatic irradiation (100-500 cGy in 5-10 fractions) induces transient (3-6 months) reduction in organomegaly but can be associated with severe pancytopenia. [38] [39] [40] JAK inhibitor therapy JAK inhibitor ATP mimetics generally have substantial activity against hydroxyurea-refractory splenomegaly (Table 1) . Their effect in this regard is rapid and often evident within the first cycle of treatment, with peak response being observed in the first 3 months of treatment. Approximately 40% of patients achieved 'Clinical Improvement' per International Working Group for MPN Research and Treatment 41 criteria (that is, minimum 50% reduction in palpable splenomegaly of a spleen that was at least 10 cm at baseline or a spleen that is palpable at more than 5 cm at baseline becomes not palpable) after 6 months of treatment with INCB018424 or TG101348. 42, 43 JAK inhibitor-induced spleen responses are usually dose-dependent and their full realization is often hampered by necessary dose reduction because of drug-related thrombocytopenia or anemia. Spleen responses were durable through 12 cycles of treatment in patients who remained on therapy. In our experience, markedly enlarged spleens (X15-20 cm below the costal margin) were less likely to exhibit complete resolution.
Maintenance of spleen response requires continued therapy; discontinuation of treatment is associated with relapse of splenomegaly, which can be rapid and sometimes distressing to patients (INCB018424; within days) or more gradual (TG101348; within weeks). The distinct time course of splenomegaly relapse likely relates to the dissimilar half-lives of INCB018424 and TG101348 (2-3 h versus 16-34 h, respectively), but also to greater off-target JAK1 activity seen with INCB018424. Relapse of splenomegaly with INCB018424 discontinuation occurs on a time-scale that is too short for regrowth of the malignant clone; consequently, it may instead reflect vascular or angiogenic phenomena associated with loss of INCB018424's well demonstrated anti-cytokine effect that is mediated primarily by JAK1 inhibition. 44 In contrast, TG101348 likely reduces splenomegaly through direct activity against the malignant clone mediated primarily by JAK2 inhibition; this is consistent with its lack of significant activity on plasma cytokine levels and its salutary effect on leukocytosis, thrombocytosis and JAK2V617F allele burden. Preliminary data with CYT387 treatment showed that 37% of patients had a X50% decrease in palpable spleen size; owing to the relatively short follow-up, clinical improvement rates for spleen response had not been reported. 45 
Anemia in MF
Prevalence and clinical aspects MF-associated anemia results primarily from ineffective hematopoiesis but replacement of normal hematopoietic tissue with collagen fibrosis and hypersplenism are probably contributory. The median hemoglobin concentration in PMF patients at the time of diagnosis/initial referral is 10-11 g/100 ml and 35 to 54% of patients present with hemoglobin o10 g/100 ml. 30, 34 MF patients frequently endorse fatigue, the severity of which is out of proportion to the degree of anemia, or that is only partially alleviated with correction of anemia. 32 
Current treatment approaches
Patients with symptomatic anemia are usually treated with androgen preparations, prednisone, danazol, thalidomide, lenalidomide or erythropoiesis-stimulating agents. 46 The latter are often ineffective in transfusion-dependent patients and might exacerbate splenomegaly. 47 Otherwise, response rates to each of the aforementioned agents are in the vicinity of 20% and response durations average about 1-2 years. The addition of prednisone to low-dose thalidomide (50 mg per day) may attenuate thalidomide-associated side effects and increase the anemia response rate. 48 Lenalidomide, either as monotherapy or in combination with prednisone, can be associated with severe myelosuppression, 49, 50 and works best in the presence of del(5q31). 51 Most recently, another thalidomide analog, pomalidomide, has been shown to alleviate anemia in approximately 25% of patients with MF 52 and, interestingly, response rates were higher in the presence of JAK2V617F.
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JAK inhibitor therapy
Consistent with the expected on-target JAK2 inhibitory activity, treatment-emergent anemia has been reported with some (INCB018424, TG101348) but not other (CYT387) JAK inhibitors (Table 1 ) emergence of grade 3 or 4 anemia appears to be dose-dependent, being noted in 27 and 54% of subjects treated with INCB018424 (starting dose 25 mg b.i.d.) and TG101348 (starting dose X680 mg/day), respectively. Emergence of anemia was less frequent at lower doses of INCB018424 (16% at starting dose 10 mg b.i.d.) and TG101348 (33% at starting dose 240-520 mg/day). In contrast, preliminary data with CYT387 treatment revealed a significant anemia response rate (Table 1) ; of the patients who were evaluable for anemia response, 41% achieved Clinical Improvement per International Working Group for MPN Research and Treatment criteria (i.e. a minimum 2 g/100 ml increase in hemoglobin level in patients with o10 g/100 ml baseline or becoming transfusion-independent). 41 Only 1 of 36 patients (3%) developed treatment-emergent grade 3 or 4 anemia in that study. Patient accrual in the CYT387 study is ongoing, and the median treatment duration at the time of the interim report was only 15 weeks; consequently, the response in anemia, including its durability, remains to be confirmed as the data matures.
Constitutional symptoms
Prevalence and clinical aspects
MF patients present with a variable degree of cachexia and constitutional symptoms, which can be intractable/treatmentrefractory, and are a source of significant morbidity. These symptoms/signs are related to tumor bulk and the hypercatabolic state of increased cell turnover, as well as elevated levels of pro-inflammatory cytokines. The prevalence of constitutional symptoms at the time of diagnosis/initial referral is 27-35% in PMF. 30, 34 In a study of self-reported constitutional symptoms by MF patients, fatigue was reported by 84%, bone pain 47%, fever 18%, pruritus 50%, and night sweats 56%. 33 Fatigue is a dominant complaint, and is inadequately explained by the degree of anemia, treatment toxicity, comorbidity, age, or even the severity of MF. 32 
Current treatment approaches
Current treatments for MF are suboptimal at alleviating fatigue or other constitutional symptoms, although hydroxyurea produces modest benefit in this regard. 36 A significant challenge in the systematic analysis of treatment effects on MF-related constitutional symptoms is the lack of a validated diseasespecific patient-reported outcome (PRO) instrument.
JAK inhibitor therapy
INCB018424, TG101348 and CYT387 have all been shown to produce a significant improvement in MF-associated constitutional symptoms (Table 1 ). In the absence of a common, validated, MF-specific PRO instrument across trials, it is difficult to compare across individual drugs; in each study, however, a majority of subjects reported improvement in fatigue, night sweats, pruritus, bone pain, fever and cough. The improvement in constitutional symptoms was seen early (within the first 2 weeks). Unlike the response in splenomegaly, there was not a clear dose-dependency; at least for INCB018424, similar symptomatic improvement was seen at the 10, 15 and 25 mg b.i.d. starting dose levels, which indicates a threshold effect in terms of the dose-response relationship. For INCB018424 and TG101348, the improvements in constitutional symptoms and performance status were durable for at least a year. The median weight gain after 1 year of INCB018424 therapy was 6.6, 9.4 and 7.1 kg for patients starting treatment at 10, 15 and 25 mg b.i.d., respectively.
The choice of a primary end point in MF clinical trials
Spleen response as primary end point
Although splenomegaly is a source of significant morbidity in MF, neither its presence nor the degree of splenic enlargement is prognostically relevant in terms of overall or leukemia-free survival. In this regard, the proposed thresholds for defining 'significant' spleen response, whether a X50% decrease in palpable splenomegaly, or X35% decrease in spleen volume as determined by imaging studies, whereas clinically useful, are to some extent arbitrary, and reflect the primarily palliative rather than disease-modifying activity of anti-MF drugs.
Anemia response as primary endpoint
Unlike splenomegaly, presence of anemia (hemoglobin o10 g/ 100 ml) has been identified as one of five independent predictors for inferior survival in PMF, as per the International Prognostic Scoring System. 34 Furthermore, transfusion-dependency at the time of diagnosis, or its acquisition within a year of diagnosis, has been shown to be an International Prognostic Scoring System-independent adverse prognostic factor for survival in PMF. 54 Consequently, improvement in anemia, as defined by Clinical Improvement as per the International Working Group for MPN Research and Treatment response criteria is a rational and clinically meaningful end point for assessing treatment response; furthermore, this end point alludes to potential disease-modifying activity through relief of the severe underlying erythropoietic defect. Nevertheless, one cannot necessarily equate improvement in anemia with better survival.
Constitutional symptom response as primary end point
PROs (self-report assessments) are increasingly important in clinical research and practice. PRO refers to any outcome that is directly derived from patient report without interpretation by the health provider, and can include assessment of symptoms, functional status, general health perception and health-related quality of life. Symptoms are considered most proximal to the disease process, and can be caused by either disease or treatment; the symptom burden may be estimated from the severity of individual or combined symptom(s) most associated with a disease or treatment, as reported by the patient's perception of the impact of these same symptoms on their daily life. In December 2009, the Food and Drug Administration issued its finalized Guidance on PRO measures, which provides stringent but general (that is, not disease specific) guidelines related to use of PRO instruments as effectiveness endpoints in clinical trials for the support of new drug applications for labeling claims (http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM193282.pdf).
There is currently no disease-specific, validated PRO instrument that is available for use in clinical trials targeting MF. One instrument currently under study is the MF Symptom Assessment Form, which is an inventory to measure the symptom burden in JAK inhibitors in myelofibrosis A Pardanani et al MF, with a focus on disease-specific symptoms such as pruritus, fatigue and splenomegaly-related symptoms. 33 Although development of the MF Symptom Assessment Form reflects a significant step forward, it has not been validated thus far for its ability to detect changes in symptom burden in MF patients, within the context of a clinical trial. A bigger question, however, is the exact role of the PRO-derived endpoints in a clinical trial for MF. Despite the significant symptom burden in MF patients, the MF Symptom Assessment Form or similar PRO instrument endpoints have been used as a secondary endpoint in treatment trials to date, with physiologic measures (that is, anemia or spleen response and so on) serving as the primary endpoint. In this case, the clinical trial would need to succeed on the physiologic endpoint before PRO-outcome measures could be used to support labeling claims based on achieving success on the secondary endpoints.
Future directions
Outstanding questions pertinent to future use of JAK inhibitors for MF treatment, including in the context of a registration trial, include the following.
What is the optimal starting dose?
While the dose-response relationship dictates that the maximum tolerated dose is the most efficacious dose, it is also generally associated with the highest incidence of adverse effects. The majority of subjects who started treatment with INCB018424 or TG101348 at the MTD (25 mg b.i.d. and 680 mg q.d., respectively) eventually required dose reduction for treatmentrelated toxicity. For INCB018424, the 10 or 15 mg b.i.d. doses were much better tolerated. Similarly, for TG101348, a starting dose of 400-500 mg per day may provide an optimal balance of risk to benefit in MF patients.
What is the optimal dosing strategy?
MF is a heterogeneous disease and a dynamic dosing schedule that triggers pre-defined dose changes if specific thresholds for response are not met, or if specific thresholds for adverse events are met, would maximize the opportunity for identifying a patient-specific optimal dose. For instance, patients with post-PV MF generally have a higher baseline hemoglobin level and are more tolerant of dose-related myelosuppression than are PMF patients. A future dosing strategy may also involve an 'induction-maintenance approach', wherein a higher dose is initially employed to maximize cytoreduction until specific response criteria are met, followed by a lower dose to maintain response. Anecdotally, several patients who needed red blood cell transfusion after starting TG101348 treatment, lost this requirement when the dose was subsequently reduced at the discretion of the investigator.
Can the inhibitor be stopped abruptly or does it need a gradual taper?
Discontinuation of a JAK inhibitor is virtually universally associated with eventual relapse of disease-associated symptoms and spleen regrowth. In rare instances, particularly at higher doses, this process can be distressing and associated with hemodynamic instability, particularly in patients with preexisting cardiopulmonary problems. In our experience the latter is more commonly observed with inhibitors that have a short halflife and significant off-target JAK-1 activity. The time course of acute relapse suggests a phenomenon that is mediated by a cytokine 'flare'. In such instances, a gradual taper of the drug over a 2-4-week period generally obviates the symptoms and signs of acute disease relapse.
Does reduction in JAK2V617F allele burden correlate with clinical response?
It needs to be emphasized that MF is a molecularly heterogeneous disease, unlike, for instance, chronic-phase chronic myelogenous leukemia; consequently, MF patients may harbor one or more mutations/cytogenetic abnormalities of potential pathogenetic relevance. Furthermore, MF patients who harbor JAK2V617F, may exhibit an allele burden that ranges from the limit-of-detection (B1%) to 100%; individual patients at the two extremes of allele burden are likely biologically dissimilar despite the shared mutation. Given the aforementioned reasons and the small number of patients treated with JAK inhibitors thus far, it is important to refrain from interpreting treatment-related changes in JAK2V617F allele burden as a primary response criterion, but instead to view it as a marker for drug activity against the malignant clone.
Is there a role for JAK inhibitors in the treatment of other MPN?
JAK-2-selective inhibitors such as TG101348 appear to have significant anti-myeloproliferative activity; the majority of subjects with leukocytosis/thrombocytosis at baseline normalized their blood counts with TG101348 treatment and some have experienced a significant reduction in JAK2V617F allele burden. Preliminary data suggested a somewhat less potent activity of INCB018424 at normalizing the platelet count in ET patients. 55 Therefore, more JAK2-specific JAK inhibitors might have a role for the treatment of PV and ET, with the caveat that long-term safety is first demonstrated.
Can treatment-related myelosuppression, particularly anemia, be averted or attenuated by combining JAK inhibitors with other agents?
This is an avenue that will be explored once longer-term safety data for JAK inhibitors becomes available. Agents with nonoverlapping toxicities that have efficacy in terms of anemia response such as pomalidomide, androgens or erythropoietin are candidates in this regard. Ex vivo studies have previously demonstrated a 'therapeutic window' in terms of selectivity of TG101348 for inhibiting JAK2V617-mutant vs wild-type progenitor cells, an effect that is amplified by use of exogenous erythropoietin, which may 'rescue' wild-type cells (relative to mutant cells) in the presence of inhibitor. 56 In conclusion, JAK inhibitors have an important role in the treatment of MPN; current data suggests a clinically meaningful palliative benefit for MF patients. Interestingly, similar palliative benefit has been noted in clinical trials using non-ATP mimetic JAK2 inhibitors, such as givinostat. 57 The absence of diseasemodifying activity is not surprising given the underlying clonal complexity of MPN. Currently available JAK inhibitors are dissimilar with regards to their side effect profile, efficacy against specific end points such as anemia, and demonstrable activity against the malignant clone vs pro-inflammatory cytokines. Maturing data from ongoing clinical trials will further refine the therapeutic role of JAK inhibitors in MPN.
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